The company manufactures and sells rubber inner tubes for a variety of vehicles including bicycles, motorcycles, and industrial machinery, while also trading tires and automotive lubricants.
The company operates in a highly commoditized industry with low net margins (3.8%) and returns on capital (9.2%) that barely exceed the cost of capital. While they have a decent distribution network, the lack of durable pricing power is evidenced by the sharp margin compression when raw material costs rise.
Profits are largely reinvested into massive capacity expansions, including a recent 50-crore tire plant funded by debt and equity. While revenue growth is high, the incremental returns on these investments are yet to be proven, and cash conversion remains extremely poor.
The company's aggressive capacity expansion, funded by debt and equity dilution, failed to generate incremental returns above the cost of capital. As raw material costs spiked, the lack of pricing power crushed the already thin 3.8% margins. The massive inventory buildup, which previously signaled growth, became a liquidity trap when cash conversion remained near zero. Ultimately, the combination of high fixed costs from the new 50-crore plant and a stagnant distribution network led to a debt spiral, while the market realized the reported earnings were never backed by actual cash flow.
RichFakir rates Viaz Tyres Ltd's business quality as poor — 40/100 on our quality score (profitability, growth, balance-sheet strength and capital allocation). We assess its competitive moat as none.
On our model, Viaz Tyres Ltd is trading far above our estimate of fair value (expensive on our lens); we rate its price expensive. This is an educational estimate from public filings, not a recommendation.
RichFakir's educational verdict on Viaz Tyres Ltd is: Avoid. We are steering clear of this one — the red flags below outweigh anything the price or numbers offer.
RichFakir's educational estimate of Viaz Tyres Ltd's fair value is about ₹20 per share, derived from public filings. It's our estimate for research — not a price target or a recommendation to buy or sell.
View the full live analysis →